Detalles de la búsqueda
1.
Antibiotic resistance of bacterial pathogens isolated from the conjunctiva in the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study (2009-2021).
Diagn Microbiol Infect Dis
; 108(1): 116069, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918187
2.
Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6.
Clin Ophthalmol
; 15: 4419-4430, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34785887
3.
Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Clin Drug Investig
; 30(10): 675-85, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20629472
4.
Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
PLoS One
; 15(8): e0237603, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32841261
5.
Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.
JAMA Ophthalmol
; 138(5): 439-450, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32271355
6.
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes.
Ophthalmol Ther
; 9(1): 159-173, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732871
7.
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies.
Clin Ophthalmol
; 13: 1427-1438, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31447544
8.
Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
Pediatr Infect Dis J
; 38(2): 138-145, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30281547
9.
The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
J Ocul Pharmacol Ther
; 34(1-2): 52-60, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-28783422
10.
Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study.
PLoS One
; 13(10): e0205814, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335799
11.
Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
Curr Eye Res
; 43(1): 43-51, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29120262
12.
Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
Ocul Immunol Inflamm
; 25(2): 267-274, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26788833
13.
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Drugs R D
; 17(1): 167-175, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28078599
14.
Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
JAMA Ophthalmol
; 133(12): 1445-54, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26502312
15.
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.
Clin Ophthalmol
; 9: 843-52, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25999691
16.
Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
BMC Psychiatry
; 4: 28, 2004 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-15458569
17.
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.
Clin Ophthalmol
; 7: 299-312, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23430378
18.
Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.
Int J Inflam
; 2012: 789623, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22536546
19.
Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Paediatr Drugs
; 14(2): 119-30, 2012 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22292487
20.
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Clin Ophthalmol
; 6: 1987-96, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23233796